Business & Economy · 54 views
AbbVie's biggest deal since 2019 could land soon
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 54 Community interest
Brief read Under 1 min brief 34 words
Summary
AbbVie ( ABBV ) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
Part of Abbvie coverage 5 tracked stories
More from Business & Economy
Continue reading recent Business & Economy coverage
- U.S. reportedly strikes Iran's Qeshm Island as Vance hopes for ‘negotiated settlement’ with TehranContinue reading
- Before the tragic Learjet crash, Adam Robinson had a message for startup founders: You don't need VCs to get richContinue reading
- UK and EU agree draft deal to scrap Brexit red tape over food exportsContinue reading
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is overContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow